Necrotising myositis in Behçet’s disease: characteristic features on magnetic resonance imaging and a review of the literature

H Sarui, T Maruyama, I Ito, N Yamakita, N Takeda, M Nose, K Yasuda

Myositis is rarely associated with Behçet’s disease. We report such a case with characteristic magnetic resonance imaging (MRI) findings, and review the literature.

CASE REPORT
A 29 year old man was first admitted to Matsunami General Hospital because of high fever and muscle pain of both lower legs, finally resulting in him being unable to walk. Painful multiple subcutaneous nodules of both lower legs and the left arm were seen. There was no history of trauma. Total leucocytes, erythrocyte sedimentation rate, and C reactive protein were raised. The serum creatine kinase value was normal. An MRI study of the lower legs (fig 1) showed a focal mass-like lesion, about 3 cm in diameter, in the left gastrocnemius muscle with a decreased intensity on a T1 weighted image compared with that for normal muscle. Gadolinium enhanced T1 weighted images showed a well defined rim of contrast enhancement and a hypointense central area. An axial T2 weighted image showed bright signal intensity in and around the focal mass-like lesion. The same MRI findings were seen in the other nodules of the lower legs. Computed tomography (CT) did not disclose the focal mass-like lesion. Antibiotics were not effective. The symptoms and multiple nodules resolved spontaneously about one month after admission, and the patient was discharged.

One month after discharge, he was admitted to our hospital because of a relapse, with similar symptoms. Painful multiple subcutaneous nodules of both lower legs, in different areas from those of his previous admission, were found. MRI findings of the mass lesions were similar to those of the previous admission.

On admission the patient had polyarthritis and skin lesions. Recurrent aphthous ulcerations had been noted over the previous two years. Pathergy testing was positive. A skin biopsy was performed and showed thrombophlebitis. HLA-B51 was positive. From these results, Behçet’s disease was diagnosed. A biopsy of a nodule from the left gastrocnemius muscle was carried out. Examination of the muscle biopsy specimen obtained from the nodular lesion showed an inflammatory granulation predominantly with an infiltration of neutrophils and macrophages, associated with focal central necrosis of the muscle and perivasculitis in the surrounding muscular tissue. A culture of the tissue specimen was negative for bacteria. These findings were consistent with necrotising myositis.

The symptoms and multiple nodules of the legs resolved spontaneously. After discharge, colchicine was given, and no painful multiple subcutaneous nodules have reappeared.

DISCUSSION
We reviewed nine cases of Behçet’s disease with myositis reported in English and the present case (table 1). Three were generalised and seven were localised myositis. Painful multiple nodules were not described in the cases. All of the localised cases involved the legs. In our case the histological findings were similar to most of the other reported localised cases; it seems possible that vasculitis as a component of Behçet’s disease may participate in the pathogenesis of myositis.

MRI has proved to be better than CT scans for the detection of soft tissue diseases—notably, muscle disorders, but was not described in the cases reviewed above. In diabetic muscle infarction and pyomyositis, a gadolinium infusion showed a slightly enhanced rim and a dark central area in T1 weighted images. Our case suggests that radiological differentiation among these lesions is difficult. A prompt biopsy and a cell culture should be carried out.

Colchicine may be useful for treating genital ulcers, erythema nodosum, and arthritis of Behçet’s disease, especially in women. In the cases reviewed here, only one patient...
received colchicine during the acute phase of myositis, with no striking effect on the myositis. In our case, necrotising myositis did not recur after the administration of colchicine. The usefulness of colchicine for prevention of myositis in Behçet’s disease needs to be further studied.

Authors’ affiliations
H Sarui, T Maruyama, I Ito, N Takeda, K Yasuda, Third Department of Internal Medicine, Gifu University School of Medicine, Japan
N Yamakita, Department of Internal Medicine, Matsunami General Hospital, Japan
M Nose, Second Department of Pathology, Ehime University School of Medicine, Japan

Correspondence to: Dr H Sarui, Third Department of Internal Medicine, Gifu University School of Medicine, 40 Tsukasa-machi Gifu 500-8705, Japan; sarui@cc.gifu-u.ac.jp

Accepted 4 March 2002

REFERENCES

Table 1  Review of Behçet’s disease with myositis in the English literature

<table>
<thead>
<tr>
<th>Patient/age (years)/sex</th>
<th>Muscle symptom</th>
<th>General symptoms*</th>
<th>Serum CK</th>
<th>Myositis</th>
<th>Recurrence</th>
<th>Histological finding of affected muscle</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/23/M</td>
<td>Nodule of right quadriceps femoris</td>
<td>Localised</td>
<td>Normal</td>
<td>Localised</td>
<td>−</td>
<td>Muscle fibre degeneration and mononuclear cell infiltration, the perimysial and endomysial connective tissue</td>
</tr>
<tr>
<td>2/42/M</td>
<td>Myalgia of both legs + ND</td>
<td>Localised</td>
<td>−</td>
<td>Localised</td>
<td>−</td>
<td>Severe muscle fibre degeneration with diffuse mononuclear infiltration; the vessels have the same type of vasculitis and perivasculitis</td>
</tr>
<tr>
<td>3/55/M</td>
<td>Myalgia of right arm + High</td>
<td>Generalised</td>
<td>Diffuse muscular necrosis and inflammation with pregnant of eroded muscle fibre</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4/25/M</td>
<td>Myalgia of right hand + ND</td>
<td>Generalised</td>
<td>Localised</td>
<td>−</td>
<td>Myositis with an inflammatory infiltrate in the interstitial and perivascular regions and focal necrosis of myocyte</td>
<td></td>
</tr>
<tr>
<td>5/14/F</td>
<td>Myalgia of both legs + ND</td>
<td>Localised</td>
<td>Normal</td>
<td>Localised</td>
<td>−</td>
<td>Infiltration of neutrophils and macrophages with focal central necrosis of muscle fibres</td>
</tr>
<tr>
<td>6/19/M</td>
<td>General progressive muscle pain and weakness</td>
<td>Generalised</td>
<td>High</td>
<td>Generalised</td>
<td>−</td>
<td>Diffuse mononuclear round cell infiltration in the perimysial and endomysial connective tissue</td>
</tr>
<tr>
<td>7/22/M</td>
<td>Myalgia of right calf + Normal</td>
<td>Localised</td>
<td>ND</td>
<td>Localised</td>
<td>+</td>
<td>Severe granulocytic-monocytic inflammation with abundant myophagocytosis and degenerating muscle fibres</td>
</tr>
<tr>
<td>8/68/F</td>
<td>General progressive muscle pain and weakness</td>
<td>Generalised</td>
<td>High</td>
<td>Generalised</td>
<td>−</td>
<td>Diffuse mononuclear round cell infiltration in the perimysial and endomysial connective tissue</td>
</tr>
<tr>
<td>9/12/M</td>
<td>Myalgia of right calf</td>
<td>Localised</td>
<td>ND</td>
<td>Generalised</td>
<td>+</td>
<td>Myositis with an inflammatory infiltrate in the interstitial and perivascular regions and focal necrosis of myocyte</td>
</tr>
</tbody>
</table>

M, male; F, female; ND, not done.
* Unspecific alterations like an increase in erythrocyte sedimentation rate, C reactive protein, body temperature, creatinine.
Systemic lupus erythematosus with haemophagocytosis and severe liver disorder

E Maeshima, T Kobayashi, M Mune, S Yukawa

We report the case of a 30 year old woman who was diagnosed with systemic lupus erythematosus (SLE) and had received prednisolone and cyclosporin A (CsA). In November 1999 a haematological examination showed a slight increase in transaminases. With no improvement in transaminase values, CsA was discontinued, and prednisolone was continued at 20 mg/day. Because of general malaise, she was admitted in January 2000.

CASE REPORT

A haematological examination showed a marked decrease in white blood cells (WBC) to $1.4 \times 10^9/l$, with a slight anaemia, but platelets were within the normal range. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were considerably increased to 617 U/l (normal 13–33) and 350 U/l (normal 6–27), respectively. Ferritin was also increased to 2306 ng/ml (normal 5–178). C reactive protein (CRP) was increased to 7.9 mg/l (normal 0–4). Anti-double stranded DNA antibodies were increased to 297.8 IU/ml (normal 0–11.9). CH50, 17 U/ml (normal 30–50) showed severe hypocomplementaemia. Soluble interleukin 2 receptor (sIL2R) was high at 807 U/ml (normal 145–519). Serum studies for hepatitis B virus, hepatitis C virus, herpes simplex virus, and Epstein-Barr virus were negative. Direct immunoperoxidase staining using a monoclonal antibody (HRP-C7) measurement, a marker of cytomegalovirus (CMV) antigenaemia, was 1/34 000. This level is associated with asymptomatic CMV antigenaemia.1,2

Bone marrow aspiration and liver biopsy were performed. In the bone marrow, histoictytic haemophagocytosis was seen (fig 1A). Liver biopsy showed moderate centrilobular large droplet fatty degeneration, hepatocellular rupture-induced lipogranuloma, and focal necrosis of hepatic cells (fig 1B). There was no lymphocyte invasion or intracytoplasmic inclusion bodies. Immunostaining was negative for CMV. Reactivated SLE associated with haemophagocytosis and a liver disorder was diagnosed. Gammaglobulin and ganciclovir were given for CMV antigenaemia. The CRP declined and CMV became negative, but fever continued. WBC decreased to $1.1 \times 10^9/l$, and AST and ALT further increased to 1081 U/l and 591 U/l, respectively, with a remarkable reduction in the CH50 to 9 U/ml.

Betamethasone was given at 6 mg/day, and CsA was resumed at 200 mg/day. Subsequently, fever abated, and the WBC increased to $3.4 \times 10^9/l$ and eventually reached normal. sIL2R fell to normal. Transaminases gradually improved, and she was discharged in April 2000. Finally, transaminases fell to the normal range in June 2000.

DISCUSSION

Possible causes of haemophagocytosis include viral infections in this patient, as well as SLE itself, because the disease was active. However, owing to the negative results of serum studies for several viruses, SLE itself was thought to be the cause of haemophagocytosis.

sIL2R, a marker of activated T cells, increases in active SLE or rises before activation of SLE.9,10 It is evident from these reports that activated T cells play an important part in the pathophysiology of active SLE. Both immune complex and hypocomplementaemia and also activated T cells played an important part in the mechanism of haemophagocytosis in our patient. CsA, which inhibits helper T cells,9 was effective, suggesting that cytokines also were important in the mechanism of haemophagocytosis.

In SLE, greatly increased transaminases are uncommon. In our patient, according to the definition and diagnostic criteria for CMV infection-induced hepatitis and cholangitis,11 CMV hepatitis was unlikely. Infections due to viruses other than CMV were also unlikely because no inclusion body was found. In addition, an examination of her liver did not point to a hepatic disorder induced by a thrombotic event. Steatosis found in SLE is generally accepted as a condition associated with drugs such as corticosteroids.12 However, hepatic disorder in our patient occurred as part of active SLE, and activated T lymphocytes and hypercytokinaemia played important roles as in the mechanism of haemophagocytosis, because sIL2R was high and improved as the clinical symptoms and liver transaminases improved with combined treatment with corticosteroids and CsA.

Figure 1  (A) Haemophagocytosis in bone marrow. The histiocyte showed phagocytosis of various haemopoietic cells including granulocytes, platelets, and erythrocytes. (May-Giemsa stain, original magnification $\times 1000$.) (B) The findings of hepatocytes rupture-induced lipogranuloma with focal necrosis of hepatic cells. (Haematoxylin-eosin stain, $\times 200$.)
Ultrastructural study of the muscle coat of the gastric wall in a case of systemic sclerosis

L Ibba-Manneschi, A Del Rosso, S Pacini, A Tani, P Bechi, M Matucci Cerinic

In systemic sclerosis (SSc), which affects the microcirculation and leads to fibrosis of skin and internal organs, the oesophagus and the colon are the gastrointestinal (GI) segments most commonly affected, even though other tracts can be impaired.

In SSc, a few ultrastructural examinations of the oesophageal and rectal wall have been made, but no study has been carried out on the stomach. This prompted us to examine the gastric wall of a patient with SSc by transmission electron microscopy (TEM) in order to investigate the components of the muscle coat.

CASE REPORT
In 1997 a 52 year old woman, with limited SSc (lSSc) since 1979, came to our attention. She had Raynaud's phenomenon, anticyclic antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaud's phenomenon, anticentromere antibodies, and Sjögren's syndrome. From the onset in 1979, came to our attention. She had Raynaul
in axonal transport and in electric transmembrane transmission, respectively. These observations substantiate the alterations in nervous transmission that might be responsible for GI dismotility in advanced SSc.

Small vessels of the gastric muscle wall were lined by preserved endothelial cells, and the basement membrane was sometimes thickened or laminated, or both (fig 1E). In SSc skin and rectum wall microvessels, on the contrary, swollen endothelial cells occluding the lumen, and thickened and laminated perivascular basal lamina, were seen.

In the stomach wall, the microvascular lumen was partially or completely occluded by erythrocytes and neutrophils (fig 1E), which contributed to tissue hypoperfusion and ischaemic damage. Neutrophils were also seen passing through the vascular wall into the interstitial space. Mast cells, rich in granules or partially degranulated, were present between vessels and smcs (fig 1F).

**DISCUSSION**

As far as we know this is the first study reporting ultrastructural modifications in the gastric wall of a patient with ISSc. Severe alterations of smcs and nerve components, and prominent fibrosis are the main hallmarks in the stomach of a patient with longstanding ISSc, while the microvasculature is quite preserved.

Ultrastructural studies performed up to now did not clarify whether smc alterations are primary or secondary to neural and/or vascular involvement, in the genesis of GI changes in SSc. Therefore, further studies on the GI tract of patients in the early phase of SSc are warranted in order to understand and clarify the primary target of the disease and its progression.

**ACKNOWLEDGEMENT**

We are grateful to APAI (Associazione Patologie AutoImmuni) for continuous support.

**Authors’ affiliations**

L Ibba-Manneschi, S Pacini, A Tani, Department of Anatomy, Histology and Forensic Medicine, University of Florence, Florence, Italy

A Del Rossa, M Matteucci Cerinic, Department of Internal Medicine, Rheumatology Section, University of Florence

P Bechi, Clinical Surgery, University of Florence

Correspondence to: Dr L Ibba-Manneschi, Department of Anatomy, Histology and Forensic Medicine, viale Morgagni 85, 50134, Florence, Italy; ibba@unifi.it

Accepted 4 February 2002
Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate

A Rozin, D Schapira, A Balbir-Gurman, Y Braun-Moscovici, D Markovits, D Militianu, M A Nahir

We read with interest the letters: “Is parenteral methotrexate worth trying?” by Osman and Mulherin and “Intramuscular methotrexate in inflammatory rheumatic disease” by Burbage, Gupta, and Lim. We would like to present our findings, which indicate that parenteral methotrexate (MTX) may be more efficient than oral MTX at the same dose and in the same patients with inflammatory joint disease. During the second half of 2000 we were faced with an unexpected shortage of parenteral MTX (ABIC, Israel) which lasted for more than five months, and patients were switched to oral MTX (Lederle, Germany). This gave us the opportunity to evaluate the difference in efficacy of parenteral versus oral administration of low dose MTX.

CASE REPORTS
Eight patients (seven female) with a mean age of 55 (38–70) years, who fulfilled the following criteria, were analysed retrospectively: (a) all had inflammatory joint diseases (four seropositive rheumatoid arthritis (RA), two seronegative RA (revised American Rheumatism Association criteria for RA), and two RA-like psoriatic arthropathy); (b) all were receiving parenteral MTX and were in complete clinical remission (fulfilling at least five of six criteria for complete clinical remission in RA); (c) all had an exacerbation of their disease when switched from parenteral to oral MTX at the same weekly dose and without any interval between the two treatments.

Ninety seven patients with inflammatory joint diseases were treated with parenteral MTX. Eighty one of them were faced with the drug supply shortage. Four patients remained in clinical remission for five months without MTX treatment. Eighteen who were not advised to switch immediately had an exacerbation of their disease within three weeks. The other 99 patients were switched to oral MTX without any treatment interval. Ten of the 99 patients received an oral dose more than 2.5–5 mg higher than the parenteral dose; no exacerbation occurred. Forty nine patients were switched to the same oral dose. Eight of them (16%) deteriorated and became the subject of our investigation.

The following variables were investigated: duration of the disease and of the remission period, x ray imaging (joint erosions), concurrent treatment, MTX weekly dose, EULAR disease activity score (DAS28 with three variables) at the time of relapse and two months after renewing the parenteral MTX treatment, compared with remission period.

Table 1 summarises the patients’ details. These patients did not differ from the patients who did not have an exacerbation after switching. All eight patients were in stable remission which had lasted for three years on average. Relapse occurred quite rapidly: 3–10 (mean 6) weeks after switching. The mean (SD) DAS28 activity index rose from 1.8 (0.4) to 4.9 (0.4). Within two months after reinstitution of the previous parenteral MTX marked improvement was noted from DAS28 4.9 (0.4) to DAS28 3.4 (0.6).

DISCUSSION
After oral administration MTX is rapidly but incompletely absorbed. Its bioavailability is about 70% at low doses (<10 mg/m²), approximately 15–20% lower than that of intramuscular (IM) or intravenous (IV) MTX. In addition, there is a marked interindividual and a moderate intrindividual variability in the extent of absorption of oral MTX. Oral administration in doses above 25 mg/day is associated with lower bioavailability due to the saturation of the absorption mechanism. Thus in high doses the parenteral administration is mandatory. IM MTX showed higher bioavailability than oral MTX either as tablets or as solution. However, other studies have shown a similar MTX concentration after oral, IM, or IV administration.

To compare the relative bioavailability of oral versus intramuscular administration in patients with RA, the pharmacokinetics of MTX at both the usual starting dose of 7.5 mg and at established higher maintenance doses was examined in 21 patients. Pharmacokinetics measurements were repeated six and 18 months after baseline while patients were receiving maintenance doses of MTX (17.0 (3.8) mg). The relative bioavailability of the maintenance dose was reduced by 13.5% as compared with the initial dose of 7.5 mg. The area under the curve of the serum concentration versus time curve
was significantly lower for oral than for IM administration at usual maintenance doses, but similar at an MTX dose of 7.5 mg a week. The authors concluded that clinicians using MTX should not assume constant and complete bioavailability across the dose range. The findings explained the benefit which follows the switching from oral to parenteral administration in patients receiving maintenance doses of MTX as well as the failure of the inverse switching reported here. It should be mentioned that all our patients were treated with MTX in doses higher than 7.5 mg/week and from the study of Hamilton and Kremer it seems that it is only safe to switch from IM to oral administration at a dose of 7.5 mg/week. Two other recent studies also supported a switch to parenteral MTX in patients previously intolerant of, or who have failed to respond to, oral MTX.

Various drugs currently used in RA may interact with MTX. It is known that corticosteroids do not interfere with the pharmacokinetics of MTX, whereas chloroquine may reduce gastrointestinal absorption of the drug. This might be relevant to two of our patients (Nos 5 and 6, table 1).

In conclusion, polyarthritis may be exacerbated owing to switching from parenteral to oral MTX using the same dosage. Reinstitution of IM MTX usually suppresses the disease activity.

Authors’ affiliations
A Rozin, D Schapira, A Balbir-Gurman, Y Braun-Moscovici, D Markovits, M A Nahir, B Shine Department of Rheumatology, Rambam Medical Centre and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
D Militianu, Department of Medical Imaging, Rambam Medical Centre and Faculty of Medicine

Correspondence to: Dr A Rozin, Department of Rheumatology, Rambam, Medical Centre, PO Box 9602, Haifa 31096, Israel; nahir@rambam.health.gov.il

Accepted 4 February 2002

REFERENCES
Spontaneous infectious spondylodiscitis (SIS) is an uncommon cause of low back pain in adults being most commonly described in children. Most cases in adults follow spinal treatment, and adult cases unrelated to previous spinal surgical procedures are considerably less common. In contrast with postoperative patients, in whom the most common infecting organisms isolated were Staphylococcus aureus and Staphylococcus epidermidis, a wide variety of infectious agents have been implicated in SIS, including Klebsiella species. Klebsiella oxytoca is a non-motile, Gram negative bacillus, that can be differentiated from Klebsiella pneumoniae by its inability to produce indole from tryptophan. As far as we know, this is the first case of SIS caused by K oxytoca to be reported.

CASE REPORT
A 51 year old man with an antecedent of intravenous heroin addiction and two months’ history of progressive thoracolumbar pain without fever was referred for investigation. Physical examination showed mild tenderness to palpation over D12-L1 and a painful paravertebral musculature contraction that limited movements of the back. Motor examination and deep tendon reflexes were normal. Several skin ulcers and venepuncture lesions in arms, hands, and legs were seen. The remainder of the examination was otherwise unremarkable.

Laboratory findings showed an erythrocyte sedimentation rate of 62 mm/1st h; C reactive protein 83 mg/l, and a white blood cell count of 11.6×10⁹/l with 78% polymorphonucleocytes. A chest radiograph and the remainder of the routine blood and urine determinations were normal. A Mantoux intradermor reaction test (2 UI PPD-RT23) was positive (15 mm in diameter). Serological tests for Brucella and HIV infection were negative and repeat sputum, blood, and urine cultures for bacteria and mycobacterium were also negative. Likewise, a skin ulcer specimen was examined and polymicrobial flora were isolated. A roentgenographic study of the lumbar spine showed degenerative changes and osteoporotic vertebral fractures in D12 and L1, and narrowing of the disc space at D12-L1. Magnetic resonance imaging (MRI) confirmed narrowing of the disc space at D12-L1, with end plate destruction of D12 and L1 (fig 1). Finally, a fine needle biopsy of the disc guided by computed tomography was performed and the specimen culture was positive for K oxytoca. In accordance with the antibiogram results, the patient received intramuscular ceftriaxone (2 g/day for six weeks). Two months later the patient had completely recovered and MRI showed significant improvement of the vertebral lesion.

DISCUSSION
Klebsiella species are an important cause of nosocomial and community acquired infection. Most of the Klebsiella strains implicated in invasive infections are K pneumoniae and <13% of episodes of bacteraemia by Klebsiella were due to K oxytoca. This micro-organism has been associated with urinary, respiratory, biliary tract, skin, and intravascular device infections. Although unusual, some cases of spondylodiscitis caused by K pneumoniae have been reported. However, as far as we know this is the first reported case of SIS due to K oxytoca.

The clinical presentation of this patient was similar to that reported in other cases of SIS, irrespective of the causative organism. Schoferman et al pointed out that the infectious agents which play a part in SIS may be of relatively low virulence, causing an insidious onset and a subacute clinical course. This is in contrast with primary vertebral osteomyelitis, in which patients present a more acute course with obvious infection. In our case, blood cultures were negative. Honan et al found that 10/16 patients with spontaneous discitis also had negative blood cultures, underlining this possibly low virulence, although it might also be explained by the fact that discitis is delayed with respect to the bacteraemia. Likewise, it is remarkable that in the series of Lin et al, pyogenic metastatic foci were not found in any of the 43 patients with K oxytoca bacteraemia. These issues suggest that K oxytoca may also have only a small ability to cause septic emboli and perhaps for this reason septic complications due to K oxytoca (such as SIS) are unusual.

Lin et al found that the most common underlying diseases associated with K oxytoca bacteraemia were hepatobiliary diseases, neoplastic diseases, and diabetes mellitus. Other predisposing factors were prior antimicrobial treatment, urinary catheterisation or manipulation, corticosteroid treatment, recent surgery, and respiratory assistance. In our patient, none of these situations were present. He had only an active intravenous heroin addiction, and was negative for HIV infection when the spondylodiscitis developed. Many authors have concluded that immunological dysfunction has a relatively minor role in the pathogenesis of infection in injection drug users, compared with the repeated parenteral introduction of non-sterile material. Nevertheless, some immunological disorders have been reported, such as a depression of
the blastogenic response of peripheral blood mononuclear cells to pokeweed mitogen and a depression of phagocytes, superoxide production, and bactericidal activity of polymorphonuclear cells from intravenous heroin users.\textsuperscript{19} In these patients, osteomyelitis infection is usually due to \textit{S. aureus} and \textit{P. aeruginosa}, and the skin and the oral cavity are the most common point of entry. \textit{K. oxytoca} is an unusual microorganism present in the skin, dregs being its principal source. Contamination by objects used for intravenous heroin introduction may be a possible cause of the \textit{K. oxytoca} infection in this case. Likewise, skin ulcers are extremely common in intravenous drug users. Although \textit{S. aureus} and \textit{B. haemolyticus} streptococci remain the most common isolates, other Gram negative bacilli such as \textit{Klebsiella} have an important role. Our patient had skin ulcers and these may be other possible points of entry for \textit{K. oxytoca}, but in our case this microorganism could not be isolated.

Authors’ affiliations

\textbf{J M Sabio, M López-Gómez, J Jiménez-Alonso, Service of Internal Medicine, Virgen de las Nieves University Hospital, Granada, Spain}

Correspondence to: Dr J Jiménez-Alonso, Virgen de las Nieves University Hospital, Avda Fuerzas Armadas 12, 18012 Granada, Spain; juialso@hvn.sas.cica.es

Accepted 25 February 2002

REFERENCES


Elderly onset isolated B27 associated dactylitis

A Padula, V Giasi, I Olivieri

Dactylitis, or “sausage-like” digit, is a typical manifestation of spondyloarthropathy (SpA).\textsuperscript{1–6} Although more common in psoriatic arthritis,\textsuperscript{7} dactylitis has been seen in all forms of SpA, including the undifferentiated forms (uSpA).\textsuperscript{1–6} In these latter cases, dactylitis usually occurs in association with the other clinical and radiological manifestations of SpA.\textsuperscript{1–6} However, occasionally, dactylitis may for a long time be the only clinical manifestation of the B27 associated disease process.\textsuperscript{3} This has been described in young and middle aged adults\textsuperscript{7,8} and in children.\textsuperscript{9} Recently, we observed the cases of two B27 positive subjects with elderly onset, isolated, longstanding dactylitis, which we report briefly here.

CASE REPORTS

The first patient, a 71 year old woman, was referred to us for evaluation of severe swelling and pain of the fourth finger of the right hand of nine months’ duration. Her family history was negative for SpA and other B27 associated diseases. Her medical history was unremarkable, except for hypertension. The patient denied ever having had other clinical manifestations of SpA. Physical examination disclosed a marked swelling affecting the entire digit. The flexor synovial sheaths were so swollen and tender that the patient could not flex the finger. There was no pain and swelling at the fourth metacarpophalangeal and proximal and distal interphalangeal joints. The only abnormal laboratory measure was a C reactive protein of 30 mg/l (normal <5). HLA typing showed A3, B27, and B53. Pelvis radiographs showed normal sacroiliac joints. The dactylitis was treated with steroid injections in the flexor synovial sheaths, with good results.

The second patient, a 62 year old man, had had “sausage-like digit” of the second right toe for three months when he was referred to us. His sister and aunt, examined in the previous 12 months in our department, were found to have B27 positive arthritis associated with ulcerative colitis and B27 positive elderly onset uSpA, respectively. The patient’s medical history was unremarkable and did not disclose any other manifestation of the B27 associated disease process. Physical examination showed severe dactylitis with swelling and tenderness along the flexor synovial sheaths of the second right toe. The joints of the digit were not affected. Laboratory evaluation showed an erythrocyte sedimentation rate of 30 mm/1st h and a C reactive protein of 30 mg/l. HLA typing showed A2, B27, and B45. Pelvis radiographs were normal. Dactylitis was successfully treated with steroid injections into the flexor synovial sheaths.

DISCUSSION

Our two elderly patients were unquestionably affected by B27 positive, late onset uSpA. They were B27 positive, had no history of previous manifestations of SpA, and developed an isolated severe dactylitis. In both cases clinical examination showed marked swelling and tenderness along the flexor tendon sheaths and normal metacarpophalangeal and interphalangeal joints. Recent studies with magnetic resonance
imaging and ultrasound have shown that the lesion always present in dactylitis is flexor tendon tenosynovitis and that arthritis of the adjacent joints may be absent. In addition, our studies on dactylitis have demonstrated that physical examination has a high specificity and sensitivity in diagnosing dactylitis and that, therefore, imaging techniques are not essential in routine practice. 

uSpA include forms of SpA that fail to meet criteria for the definite forms. Recent epidemiological studies using the Amor and/or the ESSG criteria for all forms of SpA have shown that uSpA is more common or as common as ankylosing spondylitis. The clinical spectrum of uSpA is wide, resulting from the various combinations of clinical and radiological manifestations. These include peripheral arthritis, peripheral enthesitis, dactylitis, inflammatory spinal pain, buttock pain, sacroiliitis, chest wall pain, acute anterior uveitis, aortic insufficiency together with conduction disturbances, each of which may also occur in isolation. In 1977 De Ceular et al described the cases of young and middle aged B27 subjects with isolated dactylitis. In 1988 Siegel and Baum reported the same situation in B27 positive children. In the past few years attention has been drawn to late onset uSpA. In 1995 we reported on 23 patients with uSpA who had the first symptom after the age of 45 years. Of these, 12 had three or more manifestations of SpA, seven showed two manifestations, and four only one. Of these four, two had peripheral enthesitis and two acute anterior uveitis. The present report expands the clinical spectrum of late onset SpA with the inclusion of isolated dactylitis.

**Authors’ affiliations**

A Padula, V Giassi, I Olivieri, Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza and Matera, Italy

**REFERENCES**


I n most studies examining the outcome of early arthritis, lupus and vasculitides are rare events, occurring in only 1–3% of cases. However, they should be diagnosed as quickly as possible. Thus, it might be worth testing patients with early arthritis for the presence of anticytoplasmic neutrophil antibodies (ANCA). Indeed, a strong positivity for ANCA might suggest that vasculitides, including Wegener’s disease and microscopic polyangiitis, were probably present before the onset of the clinical features typical of these disorders. Similarly, and in addition to looking for anti-nuclear antibodies (and/or anti-dsDNA antibodies), it has been claimed that testing for antineculeosome antibodies might be a valuable additional test for the early detection of lupus; this last subset of autoantibodies has shown good sensitivity (56%) and excellent specificity (97%) for long-standing systemic lupus erythematosus (SLE). However, these assumptions have not yet been supported by data from an inception cohort of patients with early unclassified arthritis tested by routine methods.

We tested for ANCA by indirect immunofluorescence (IIF) (1:20 dilution) and for antineculeosome-IgG by a commercial enzyme linked immunosorbent assay (ELISA) kit (BMD DNA-NUC-LISA) in the baseline sera of 270 patients with early onset arthritis without clinical signs suggestive of visceral disease. We then followed up these patients for a mean (SD) of 28.5 (12.1) months.

For the ANCA testing, although 23/270 (9%) baseline sera were positive, neither of the two patients later diagnosed as having vasculitides were positive by IIF-ANCA. Moreover, for both patients, even testing for anti-proteinase 3 (anti-PR3) and anti-myeloperoxidase (anti-MPO) by ELISA was negative at baseline.
For antinucleosome testing, at the 10 IU threshold suggested by the manufacturer, 109/270 (40%) sera were positive, including 51/114 (45%) rheumatoid arthritis (RA) and 20/34 (59%) spondyloarthropathy (SpA). However, at the 20 IU threshold only 4% were still positive, including 2/33 (6%) unclassified arthritis, 5/105 (5%) RA, 2/52 (4%) SpA, 1/5 (20%) sicca syndrome, and only 1/5 (20%) patients later diagnosed as having SLE. Moreover for this single patient, the diagnosis was already firmly established, especially as the antinuclear antibody titre was 1/1000 and anti-dsDNA were positive. Hence the positive predictive value for SLE of antinucleosome testing was 1/11, and the sensitivity 1/5.

These low sensitivities do not support the working hypothesis that systematic screening for IIF-ANCA and antinucleosome antibodies is useful for the diagnosis of vasculitides in early arthritis and of SLE in patients with “naked” arthritis. Such results were somewhat expected, given that systemic vasculitis or SLE with arthritis as precursor are quite uncommon events. However, they confirm that determination of ANCA and antinucleosome antibodies should not be carried out in the absence of clinical extra-articular manifestations, especially as low ANCA titres have already been demonstrated in a large percentage of more benign conditions like early RA and early SpA.** We would therefore quite agree with the conclusion of Merkel et al, that instead of systematic screening for ANCA by IIF, only those patients with features atypical for RA, SpA, or undifferentiated arthritis should be tested for ANCA, using an ELISA for anti-PR3 and anti-MPO together with IIF-ANCA.**

Likewise in our cohort, antinucleosome antibodies were positive at low values at baseline in several conditions other than SLE and in only 1/5 patients with SLE. There are few reports on antinucleosome antibodies and SLE, and thus definite conclusions cannot be reached about the overall additional value of this test to support the diagnosis of SLE.** However, our results strongly suggest that systematic testing for antinucleosome antibodies should not be a substitute for a careful search for all visceral signs suggestive of lupus in a patient presenting with seemingly “naked” arthritis.

ACKNOWLEDGEMENT

Funding was provided by the Centre Hospitalier de Nantes and the Programme Hospitalier de Recherche Clinique 1995.

Authors’ affiliations
J-M Berthelot, Rheumatology Unit, Nantes University Hospital, 44093, CHU, Nantes, France
A Saraux, P Le Goff, Rheumatology Unit, Brest University Hospital, 29629, CHU, Brest, France
M Audrain, J-Y Muller, Laboratory of Immunology, Nantes University Hospital, 44093, CHU, Nantes, France
M Hamidou, Internal Medicine Unit, Nantes University Hospital, 44093, CHU, Nantes, France
P Youinou, Laboratory of Immunology, Brest University Hospital, 29629, CHU, Brest, France

Correspondence to: Dr J-M Berthelot, Rheumatology Unit, CHU Nantes, Hôpital Dieu, 44093, Nantes-Cedex 01, France; jeanmarie.berthelot@chu-nantes.fr

Accepted 4 February 2002

REFERENCES

4 Wilk A. Antineutrophil cytoplasmic antibodies tests: which tests should be used in practice? Intern Med 2001;40:466–70.

Cogan’s syndrome with antineutrophil cytoplasmic autoantibody

M Ikeda, H Okazaki, S Minota

Cogan’s syndrome is a rare disease characterised by non-syphilitic interstitial keratitis with vestibuloauditory dysfunction, including loss of hearing, tinnitus, and vertigo. We report here a case of Cogan’s syndrome positive for antineutrophil cytoplasmic antibody (ANCA). This case is interesting in consideration of the pathogenesis of this syndrome.

CASE REPORT

In May 1999 a 61 year old man was admitted to our hospital with fever and myalgia localised to the lower part of both legs. He had a history of lung tuberculosis at 22 years old, chronic sinusitis at 30, and bilateral otitis media at 53. On admission, laboratory tests showed a white blood cell count of 11.2×10^9/l and a CRP level of 63 mg/l. Serum levels of creatine kinase, alanine aminotransferase, and aspartate aminotransferase, and a urinary examination were normal. A serological test was positive for perinuclear ANCA (pANCA) and myeloperoxidase ANCA (MPO-ANCA; 105 EU/ml (normal <10 EU/ml)), but negative for syphils and cytoplasmic ANCA (cANCA). Electromyographic findings were normal. Although the pathological change of vasculitis was not detected in the biopsied muscle, the presence of microscopic polyangiitis was
highly suspected based on the high titre of MPO-ANCA. Prednisolone (30 mg/day) was given at once, and after one month the levels of C reactive protein (CRP) and MPO-ANCA decreased to 5 mg/l and 12 EU/ml, respectively, with clinical improvement.

While receiving continuous prednisolone treatment, in August 2000, the patient suddenly developed severe fronto-temporal headache and vertigo. The CRP level increased to 43 mg/l. Two weeks later, complete hearing loss of his left ear developed. Immediate administration of betamethasone (10 mg/day) for three days did not improve his hearing.

In January 2001 myalgia and weight loss developed and continued, and the levels of CRP and MPO-ANCA were raised at 68 mg/l and 46 EU/ml, respectively. In February 2001 redness of both eyes due to keratouveitis suddenly occurred, which improved after treatment with corticosteroid eye drops. Cyclophosphamide (50 mg/day) was also given together with betamethasone (1.5 mg/day), and complete clinical and serological remission was observed (CRP 5 mg/l, MPO-ANCA 10 EU/ml). A diagnosis of Cogan’s syndrome was made based upon the clinical constellation of keratouveitis, sensorineural hearing loss, and suspected systemic vasculitis.

**DISCUSSION**

Previously, Cheson et al reviewed 53 cases of Cogan’s syndrome; 10/18 vessel or muscle biopsy specimens showed inflammatory vascular changes, of which four were considered to be diagnostic of polyarteritis in large and medium sized arteries. ANCA is widely used as a useful diagnostic marker for small vessel vasculitis, including Wegener’s granulomatosis, microscopic polyangiitis, pauci-immune necrotising crescentic glomerulonephritis, and Churg-Strauss syndrome, although this test is occasionally positive in various other conditions. Recently, it has been reported that the combination of immunoassays for anti-MPO and indirect immunofluorescence for pANCA is highly specific for the diagnosis of systemic vasculitis. Until now, five cases of Cogan’s syndrome associated with ANCA have been reported, including ours, and two of them also showed ANCA related glomerulonephritis. In our case, pANCA and MPO-ANCA were positive, and audiovestibular abnormalities and keratouveitis were present, but other manifestations of systemic vasculitis were not noted. We speculate, therefore, that all sizes of arteries may be affected in Cogan’s syndrome.

The cause of Cogan’s syndrome is still unknown. Interestingly, upper respiratory tract infections have been reported to precede the onset of Cogan’s syndrome in 40% of cases, suggesting that one of the triggering factors may be upper respiratory infection. Our patient also had a history of upper respiratory infections. The research group in the National Institute of Health found that patients with Cogan’s syndrome had significantly high titres of antibodies to *Chlamydia trachomatis*. Ljungstrom et al reported a patient with Cogan’s syndrome who had a fourfold increase in serum IgG antibody titre to *Chlamydia pneumoniae*. Furthermore, it has been reported that *Chlamydia* infections are related to vascular injury, such as arteriosclerosis and vasculitis. A relationship between previous *Chlamydia* infection and coronary artery disease is supported by seroepidemiological studies. It is suggested that the bacteria adhere to endothelial cells, because *Chlamydia pneumoniae* is detected in atherosclerotic plaques by both polymerase chain reaction and culture. In our case, the IgG titre to *Chlamydia pneumoniae* was negative, but the IgA titre was positive (2.23, cut off point 0.9). We suggest that the IgG titre might have been negative in our case because the titre was measured several months after treatment with corticosteroid and cyclophosphamide.

This case suggests a possibility that antinuclear antibodies are related to the pathogenesis of Cogan’s syndrome, although further studies are required to confirm this hypothesis.

**Authors’ affiliations**

M Ikeda, Health Science Centre, Utsunomiya University, Tochigi, Japan

H Okazaki, S Minota, Division of Rheumatology and Clinical Immunology, Jichi Medical School, Tochigi, Japan

Correspondence to: Dr M Ikeda, Health Science Centre, Utsunomiya University, Utsunomiya City, Tochigi 321–8505, Japan; ikedam@cc.utsunomiya-u.ac.jp

Accepted 7 January 2002

M Hamidou, Internal Medicine Unit, Nantes University Hospital, 44093, CHU, Nantes, France

P Youinou, Laboratory of Immunology, Brest University Hospital, 29629, CHU, Brest, France

Correspondence to: Dr JM Berthelot, Rheumatology Unit, CHU Nantes, Hôtel-Dieu, 44093, Nantes-Cedex 01, France; jeanmarie.berthelot@chu-nantes.fr

Accepted 4 February 2002

**REFERENCES**


CASE REPORT
A 51 year old factory worker presented with a two year history of pain and swelling of the right index and middle finger metacarpophalangeal (MCP) joints. He had no significant past medical history and there was no family history of arthritis. Examination showed bony deformity and diminished range of movement at the right index and middle MCP joints. The left hand and other joints were normal. There were no abnormalities on examination of his cardiovascular system or abdomen.

His job in a car assembly factory for the previous 10 years had involved lifting mesh car components from a container using only his right hand, and he estimated that he would carry out this manoeuvre about 4000 times in a day.

Radiographs of his right hand showed joint space narrowing and osteophytes at the right second and third MCPs (fig 1A). The left hand was radiologically normal (fig 1B).

His rheumatoid factor, blood count, and erythrocyte sedimentation rate were negative/normal. Serum alkaline phosphatase was 150 U/l (normal 30–130). Fasting glucose was 5.8 mmol/l. Serum ferritin was 1184 ng/ml (normal 20–350) with a serum iron of 42 µmol/l (normal 20–30). Genetic studies showed him to be homozygous for the Cys282 Tyr mutation, the genotype found in over 90% of patients with haemochromatosis in the UK. He was diagnosed with haemochromatosis and treated by venesection.

His family members have been screened for the condition. One son aged 29 years has been found to have a transferrin saturation of 60%. Ferritin level is normal. Genetic testing has been carried out and shown him to be a compound heterozygote with Cys282 Tyr and His 63 Asp mutations, a genotype associated with haemochromatosis in 20% of cases. He is at present being kept under surveillance.

DISCUSSION
There have been reported cases of undiagnosed haemochromatosis presenting as exercise related joint pains in recreational runners with underlying haemochromatosis arthropathy. However, this patient’s unilateral arthritis suggests that minor trauma may interact with genetic haemochromatosis to determine the distribution of joint damage. This is consistent with the observation of Lee et al, who described unilateral arthropathy on the normal side of a patient with haemochromatosis and a hemiparesis.

Whether the course of arthritis is altered by venesection is unclear. However, it is important to make an early diagnosis of haemochromatosis in a patient presenting with arthropathy because venesection may prevent internal organ damage.

Authors’ affiliations
C Morgan, General Medicine, Morriston Hospital, Swansea, UK
D Smith, Rheumatology Department, Morriston Hospital, Swansea, UK

Correspondence to: Dr C Morgan, 95 Romilly Crescent, Pontcanna, Cardiff CF11 9NG, UK; carysmorgan@hotmail.com

Accepted 5 February 2002

REFERENCES